ANIP - MCAP CO - ANI Pharmaceuticals

The visual price action for ANI Pharmaceuticals (ANIP) on GURU.Markets demonstrates metrics at the level of 1.70. ANI Pharmaceuticals generates revenue through the sale of Cortrophin, the integration of Alora assets, and profit growth. Logistics rely on distributed warehouses and diverse raw material sources to eliminate supply disruptions. Business development is based on licensing agreements and partnerships with major wholesalers for the distribution of orphan drugs.

ANI Pharmaceuticals maintains stable margins through flexible supply chain management of scarce generics and the diversification of its raw material base. This operational resilience translates into market capitalization—calculated as the share price multiplied by the total number of outstanding securities—reflecting the aggregate investor consensus on the scale of the business, as clearly demonstrated by the company's current market value.